FrancophonIA/ELRC3.0 huggingface dataset:
English: Adopted by CVMP in May 2004
Danish: Vedtaget af CVMP i maj 2004
English: March 2004
Danish: marts 2004
English: The Oncology SAG, SAG on Diagnostics and SAG on Anti-infectives were the first SAGs created by the Committee.
Danish: De første SAG, udvalget nedsatte, vedrørte henholdsvis onkologi, diagnostik og antibiotika.
English: Scientific Advisory Group on Antimicrobials Chair: Liisa KAARTINEN EMEA contact: Kornelia GREIN
Danish: antimikrobielle stoffer Formand: Liisa KAARTINEN EMEA-kontakt: Kornelia GREIN
English: LATVIA
Danish: LETLAND
English: Czech Republic
Danish: TJEKKIET
English: CZECH REPUBLIC
Danish: Tjekkiet
English: Adopted in December 2003
Danish: Vedtaget i december 2003
English: Pharmacogenetics Working Party (formerly Ad hoc Expert Group on Pharmacogenetics)
Danish: Arbejdsgruppen vedrørende farmakogenetik (tidl. ad hoc-ekspertgruppen vedr.
English: 346 days
Danish: 196 days 346 days
English: 3 Replaced Pavel VEC as of July 2004 meeting.
Danish: 3 Trådte i stedet for Pavel ŠVEC fra juli 2004.
English: Medicines for human use - Highlights in 2004
Danish: Humanmedicinske lægemidler - Vigtigste begivenheder i 2004
English: Scientific advice requests received
Danish: Anmodninger om videnskabelig rådgivning
English: Evaluation time for type-IA variations 2004
Danish: Vurderingstid for type IA-ændringer
English: • Pharmacovigilance Working Party
Danish: • Arbejdsgruppen vedrørende lægemiddelovervågning
English: CHMP Blood Products Working Party
Danish: CHMP's arbejdsgruppe vedrørende blodpræparater
English: Greece
Danish: GRÆKENLAND
English: GREECE
Danish: Grækenland
English: Pharmacovigilance Working Party Chair: Cornelia IBRAHIM EMEA contact: Kornelia GREIN
Danish: Arbejdsgruppen vedrørende lægemiddelovervågning Formand: Cornelia IBRAHIM EMEA-kontakt: Kornelia GREIN
English: Scientific Advice Working Party Chair: Reinhard KROKER EMEA contact: Jill ASHLEY-SMITH
Danish: Formand: Reinhard KROKER EMEA-kontakt: Jill ASHLEY-SMITH
English: Evaluation time for type-IB variations 2004
Danish: Vurderingstid for type IB-ændringer
English: Support was provided through scientific and regulatory training for committee members, experts and assessors.
Danish: De nye medlemsstater fik støtte i form af undervisning af udvalgsmedlemmer, eksperter og bedømmere i de videnskabelige problemstillinger og relevante retsforskrifter.
English: Purevax RCP
Danish: Purevax RCP FeLV
English: Evaluation time for type-II variations (90-day procedure)
Danish: Vurderingstid for type II-ændringer 90-dages procedure)
English: Details of these can be found in Annex 13.
Danish: Bilag 13 indeholder nærmere enkeltheder om disse sager.
English: 801 days
Danish: 177 days 801 days
English: Working parties of the CHMP
Danish: CHMP's arbejdsgrupper
English: Document management and publishing
Danish: Styring og offenliggørelse af dokumenter
English: COMP opinions in 2004 on designation of orphan medicinal products 12.
Danish: COMP-udtalelser i 2004 om lægemidler til sjældne sygdomme 12.
English: The number of applications for orphan medicinal products remained relatively stable in 2004, with 10 applications.
Danish: Der indkom 10 ansøgninger for lægemidler til sjældne sygdomme i 2004, dvs. nogenlunde det samme som tidligere år.
English: DENMARK
Danish: Danmark
English: Sweden
Danish: SVERIGE
English: Marketing authorisation holder
Danish: Indehaver af markedsføringstilladelse
English: Pre-submission meetings
Danish: Møder forud for indgivelse af en ansøgning
English: 141 days
Danish: 210 days 141 days
English: Total title 3
Danish: Afsnit 3 i alt
English: Unit for the pre-authorisation evaluation of medicines for human use Head of Unit
Danish: Afdelingen for vurdering af humanmedicinske lægemidler før godkendelse Afdelingsleder
English: SPAIN
Danish: Spanien
English: Spain
Danish: SPANIEN
English: Part B
Danish: Zonegran zonisamide Part B
English: 124 days
Danish: 120 days 124 days
English: It also ensures the Agency s risk management and liaises with the European Commission s Internal Audit Service.
Danish: Revisionssektionen samarbejder med Den Interne Revisionstjeneste i Europa-Kommissionen.
English: Head of Sector for safety of veterinary medicines
Danish: Sektionsleder - veterinærlægemidlers sikkerhed
English: Head of Sector for scientific advice and orphan drugs
Danish: Sektionsleder - videnskabelig rådgivning og lægemidler til sjældne sygdomme
English: For enquiries concerning certificates for centrally authorised medicines for human or veterinary use:
Danish: certifikater for human- eller veterinærmedicinske lægemidler godkendt efter den centraliserede procedure:
English: POST-AUTHORISATION EVALUATION OF MEDICINES FOR HUMAN USE
Danish: VURDERING AF HUMANMEDICINSKE LÆGEMIDLER EFTER GODKENDELSE
English: Paediatric Working Party (formerly Paediatric Expert Group)
Danish: Arbejdsgruppen vedrørende pædiatri (tidl. ekspertgruppen vedr.
English: Type-I variations Type-II variations Extensions
Danish: Produktserieudvidelser Type II-ændringer Type I-ændringer
English: Integrated quality management
Danish: Integreret kvalitetsstyring (IQM)
English: 467 days
Danish: 118 days 467 days
English: Genito-urinary system and sex hormones
Danish: Kønsorganer/urinvej
English: LITHUANIA
Danish: LITAUEN
English: Substance INN
Danish: Produkt Handelsnavn INN
English: NETHERLANDS
Danish: NEDERLANDENE
English: • Scientific Advice Working Party
Danish: • Arbejdsgruppen vedrørende videnskabelig rådgivning
English: Chair: Michel MARTY EMEA contact: Agnès SAINT-RAYMOND
Danish: Formand: Michel MARTY EMEA-kontakt: Agnès SAINT-RAYMOND
English: European product index http://heads.medagencies.org/mrindex/index.html
Danish: Styrelseschefer - humanmedicinske lægemidler http://heads.medagencies.org Europæisk produktindeks http://heads.medagencies.org/mrindex/index.html
English: Art. 29(2) of Directive 2001/83/EC (previously Art. 10(2) of Directive 75/319/EEC)
Danish: Art. 29, stk. 2, i direktiv 2001/83/EF (tidl. art. 10, stk. 2, i direktiv 75/319/EØF)
English: Structure of the EMEA
Danish: EMEA's organisationsplan
English: The revised legislative package has significant impact on the Agency.
Danish: Den reviderede lovpakke har stor betydning for agenturets virke, idet den indebærer nye ansvarsområder og en ny administrativ struktur.
English: Date of CHMP opinion International non-proprietary name (INN)
Danish: Internationalt fællesnavn (INN)
English: Adopted in July 2004
Danish: Vedtaget i juli 2004
English: The EMEA started the implementation of the newly established procedure for the handling of safety concerns in relation to centrally processed applications in April 2004, with a pilot phase based on selected medicines undergoing evaluation for marketing authorisation.
Danish: I april 2004 påbegyndte EMEA implementeringen af den nye procedure for håndteringen af sikkerhedsaspekterne ved centralt behandlede ansøgninger.
English: Adopted in February 2004
Danish: Vedtaget i februar 2004
English: For matters relating to pharmacovigilance for medicinal products for veterinary use:
Danish: Spørgsmål vedrørende lægemiddelovervågning af veterinærlægemidler:
English: EMEA annual report for 2004 EMEA/61492/2005/EN/Final
Danish: EMEA's årsberetning for 2004 EMEA/211642/2005/da/endelig udg.
English: The CVMP adopted its Guideline on harmonising the approach to causality assessment for adverse reactions in order to ensure greater consistency throughout the EU in reporting adverse events by all parties involved.
Danish: CVMP vedtog retningslinjer for harmonisering af fremgangsmåden ved vurdering af årsagssammenhængen i forbindelse med bivirkninger.
English: 243 days
Danish: 210 days 243 days
English: Pharmacovigilance and postauthorisation safety and efficacy of medicines
Danish: Lægemiddelovervågning og lægemidlers sikkerhed og virkninger efter godkendelse
English: Overview
Danish: Oversigt
English: Significant variations/new treatment options for patients suffering from HIV/AIDS
Danish: Vigtige ændringer/nye behandlingsmuligheder for hiv/aids-patienter
English: Acting Deputy Head of Sector for scientific advice and orphan drugs
Danish: Fungerende vicesektionsleder - videnskabelig rådgivning og lægemidler til sjældne sygdomme
English: Evaluation in < 60 days Evaluation in 60-120 days Evaluation in > 120 days
Danish: Vurdering 60-120 dage
English: Released for consultation in February 2004
Danish: Sendt til høring i februar 2004
English: Release for consultation expected in 2nd quarter 2005
Danish: Forventes sendt til høring i 2. kvartal 2005
English: Mimpara !
Danish: Anmodn.
English: POLAND
Danish: Polen
English: Poland
Danish: POLEN
English: Scientific Advice Working Party
Danish: Arbejdsgruppen for videnskabelig rådgivning
English: One PMF was finalised.
Danish: En ansøgning blev færdigbehandlet.
English: Unit for the post-authorisation evaluation of medicines for human use Head of Unit
Danish: Afdelingen for vurdering af humanmedicinske lægemidler efter godkendelse Afdelingsleder
English: Working Group with Interested Parties Chair: Yann LE CAM/Agnès SAINT-RAYMOND EMEA contact: Spiros VAMVAKAS
Danish: Arbejdsgruppen med interesserede parter Formand: Yann LE CAM/Agnès SAINTRAYMOND
English: Committee on Orphan Medicinal Products (COMP)
Danish: Udvalget for Lægemidler til Sjældne Sygdomme (COMP)
English: Periodic safety update reports
Danish: Periodiske opdaterede sikkerhedsindberetninger 2002-2004
English: Firocoxib !
Danish: Previcox Firocoxib Part B
English: Adopted in March 2004
Danish: Vedtaget i marts 2004
English: Accounting
Danish: Bogholderi
English: Organisation of scientific advice at the Agency
Danish: Organiseringen af EMEA's videnskabelige rådgivning
English: Number of payments processed
Danish: Modtagne betalinger
English: To deploy a scientific advice database
Danish: Udvikling af en database over videnskabelig rådgivning
English: Release for consultation expected in 3rd quarter 2005
Danish: Forventes sendt til høring i 3. kvartal 2005
English: Musculoskeletal and nervous systems
Danish: Neurologi/centralnervesystemet
English: o Feline viral rhinotracheitis o Calcivirus infection o Chlamydophilia felis infection o Feline panleucopenia o Feline leukaemia
Danish: o calcivirusinfektion o Chlamydophilia felis-infektion o kattesyge (panleucopenia)
English: 207 days
Danish: 177 days 207 days
English: Scientific Advisory Group on Anti-infectives (formerly Therapeutic Advisory Group on Antiinfectives)
Danish: Videnskabelig arbejdsgruppe vedrørende antibiotika (tidl. terapeutisk rådgivende gruppe vedr.
English: HUNGARY
Danish: Ungarn
English: Hungary
Danish: UNGARN
English: Members of the Committee for Medicinal Products for Human Use
Danish: Medlemmer af Udvalget for Lægemidler til Sjældne Sygdomme
English: Adopted in November 2004
Danish: Vedtaget i november 2004
English: 113 days
Danish: 210 days 113 days
English: Adopted in June 2004
Danish: Vedtaget i juni 2004
English: Significant variations/new treatment options for patients suffering from cancer
Danish: Vigtige ændringer/nye behandlingsmuligheder for cancerpatienter
English: Mean duration of scientific advice procedures
Danish: sagsbehandlingstid for videnskabelig rådgivning
English: EMEA contact: John PURVES
Danish: celleterapi) Formand: Pekka KURKI EMEA-kontakt: John PURVES
English: Art. 36 of Directive 2001/83/EC (previously Art. 15(a) of Directive 75/319/EEC)
Danish: Art. 36 i direktiv 2001/83/EF (tidl. art. 15, litra a), i direktiv 75/319/EØF)
English: 162 days
Danish: 184 days 162 days
English: 577 days
Danish: 217 days 577 days
English: Adopted in October 2004
Danish: Vedtaget i oktober 2004
English: Anti-infectives
Danish: Antibiotika
English: The number of applications for orphan medicinal product designation withdrawn by sponsors in 2004 was 22.
Danish: COMP vedtog 4 negative udtalelser i 2004, og 22 ansøgninger om udpegelse af lægemidler til sjældne sygdomme blev tilbagekaldt af sponsorerne.
English: Released for consultation in January 2004
Danish: Sendt til høring i januar 2004
English: Adopted in April 2004
Danish: Vedtaget i april 2004
English: Adopted in January 2004
Danish: Vedtaget i januar 2004
English: Art. 30 of Directive 2001/83/EC (previously Art. 11 of Directive 75/319/EEC)
Danish: Art. 30 i direktiv 2001/83/EF (tidl. art. 11 i direktiv 75/319/EØF)
English: 221 days
Danish: 181 days 221 days
English: Details of all referrals are given in Annex 13.
Danish: De videnskabelige retningslinjer er nærmere omhandlet i bilag 10.
English: Useful websites: International Conference on Harmonisation http://www.ich.org
Danish: http://www.ich.org International harmoniseringskonference (veterinærlægemidler)
English: CHMP Pharmacovigilance Working Party
Danish: CHMP's arbejdsgruppe vedrørende lægemiddelovervågning
English: CVMP Pharmacovigilance Working Party
Danish: CVMP's arbejdsgruppe vedrørende lægemiddelovervågning
English: To upgrade the Experts database and make it available to all NCAs
Danish: Opgradering af databasen over eksperter.
English: Significant variations/new treatment options for patients suffering from diabetes
Danish: Vigtige ændringer/nye behandlingsmuligheder for diabetespatienter
English: Zonegran !
Danish: modt.
English: Adopted in December 2004
Danish: Vedtaget i december 2004
English: Annex 4 Members of the Committee on Orphan Medicinal Products
Danish: Bilag 2 Medlemmer af Udvalget for Humanmedicinske Lægemidler
English: 118 days
Danish: 118 days 0 days
English: • Assessment report templates to harmonise and facilitate the assessment review by the CHMP during the evaluation of the dossier pre-/post-authorisation were updated to take into consideration the changes of the European pharmaceutical legislation, especially Annex 1 of Directive 2001/83/EC.
Danish: • Der er foretaget en ajourføring af skabeloner til vurderingsrapporter for at harmonisere og lette CHMP's vurderingsundersøgelser i forbindelse med sagsbehandlingen før og efter godkendelse.
English: 631 days
Danish: 244 days 631 days
English: Released for consultation in September 2004
Danish: Sendt til høring i september 2004
English: Release for consultation expected in 1st quarter 2005
Danish: Forventes sendt til høring i 1. kvartal 2005
English: Released for consultation in November 2004
Danish: Sendt til høring i november 2004
English: Released for consultation in October 2004
Danish: Sendt til høring i oktober 2004
English: Head of Sector for pharmacovigilance and post-authorisation safety and efficacy of medicines
Danish: Sektionsleder - lægemiddelovervågning og tilsyn med lægemidlers sikkerhed og virkninger efter godkendelse
English: 297 days
Danish: 215 days 297 days
English: • Romaldas MACIULAITIS (Lithuania) Alternate: Mykolas MAURICAS
Danish: • Romaldas MACIULAITIS (Litauen)
English: Head of Sector for safety and efficacy of medicines
Danish: Sektionsleder - lægemidlers sikkerhed og virkninger
English: An initial evaluation is conducted by the EMEA to assess the quality, safety and efficacy of every new veterinary product that is subject to the Community or centralised procedure.
Danish: EMEA foretager en indledende vurdering for at vurdere sikkerheden ved og kvaliteten og virkningerne af alle nye veterinærlægemidler, der søges godkendt efter EU-proceduren (den centraliserede procedure), hvorefter CVMP vedtager en udtalelse om, hvorvidt der bør gives markedsføringstilladelse for produktet.
English: Art. 31 of Directive 2001/83/EC (previously Art. 12 of Directive 75/319/EEC)
Danish: Art. 31 i direktiv 2001/83/EF (tidl. art. 12 i direktiv 75/319/EØF)
English: 6.2 Information technology at the EMEA..................................................................................74
Danish: 6.2 Informationsteknologi i EMEA...........................................................................................74
English: 289 days
Danish: 197 days 289 days
English: Revision adopted in June 2004
Danish: Revideret udgave vedtaget i juni
English: • Alistair KENT (patients organisation representative)
Danish: • Alistair KENT
English: 213 days
Danish: 182 days 213 days
English: The year 2004 saw the establishment of a new scientific committee at the EMEA, following the entry into force of Title IV of Regulation (EC) No 726/2004 and the Directive on Herbal Medicinal Products.
Danish: Efter at afsnit IV i forordning (EF) nr. 726/2004 og direktivet om plantelægemidler var trådt i kraft, blev der i 2004 nedsat et nyt videnskabeligt udvalg i EMEA.
English: • Gene Therapy Working Party
Danish: • Arbejdsgruppen vedrørende genterapi
English: Date of regulation !
Danish: om udpeg.
English: • David LYONS (EMEA representative) • Henri METZ (Luxembourg)
Danish: • David LYONS (EMEA-repræsentant)
English: • Steffen THIRSTRUP6 (Denmark) Alternate: Jens ERSBØLL7
Danish: • Steffen THIRSTRUP6 (Danmark)
English: To ensure the timely back-up and archiving of the EMEA data, including off-site disaster recovery scenarios
Danish: Rettidig arkivering og backup af EMEA-data, inkl.
English: 154 days
Danish: 184 days 154 days
English: SLOVAKIA
Danish: SLOVAKIET
English: CHMP Safety Working Party
Danish: CHMP's arbejdsgruppe vedrørende sikkerhed (SWP)
English: 173 days
Danish: 60 days 173 days
English: Gene Therapy Working Party (formerly Ad hoc Expert Group on Gene Therapy)
Danish: Arbejdsgruppen vedrørende genterapi (tidl. ad hoc-ekspertgruppen vedr.
English: Live Vaccine !
Danish: og immunmodul.
English: SLOVENIA
Danish: SLOVENIEN
English: Re-release for consultation expected in 1st quarter 2005
Danish: Forventes sendt til ny høring i 1. kvartal 2005
English: TOTAL REVENUE
Danish: INDTÆGTER I ALT
English: Deputy Head of Sector for pharmacovigilance and post-authorisation safety and efficacy of medicines
Danish: Vicesektionsleder - lægemiddelovervågning og tilsyn med lægemidlers sikkerhed og virkninger efter godkendelse
English: In total, 61 518 ICSRs were reported electronically to EudraVigilance in 2004, referring both to reports for centrally authorised medicinal products as well as those authorised through the mutual recognition and national procedures.
Danish: Tallet omfatter indberetninger for både centralt godkendte lægemidler og lægemidler, der er godkendt i henhold til proceduren for gensidig anerkendelse eller nationale procedurer.
English: Building/equipment
Danish: Tjeneste eller projekt
English: 236 days
Danish: 194 days 236 days
English: 129 days
Danish: 181 days 129 days
English: Cardiovascular
Danish: Kardiovask.
English: CHMP Invented Name Review Group
Danish: CHMP's arbejdsgruppe vedrørende revision af særnavne
English: Consultation ended in September
Danish: Høring afsluttet i september 2004
English: • Efficacy Working Party
Danish: • Arbejdsgruppen vedrørende virkninger
English: CVMP Efficacy Working Party
Danish: CVMP's arbejdsgruppe vedrørende virkninger
English: Finalisation expected in 1st quarter
Danish: Forventes afsluttet i 1. kvartal 2005
English: Clinical trial phases of scientific advice requests 2004
Danish: efter klinisk undersøgelsesfase - 2004
English: 356 days
Danish: 228 days 356 days
English: 180 days
Danish: Vurdering > 180 dage
English: • Ján MAZÁG3 (Slovakia) Alternate: Leila FARAH
Danish: • Ján MAZÁG3 (Slovakiet)
English: In 2004, a wide range of user, technical and NCA training was successfully provided to EMEA staff and delegates alike.
Danish: I 2004 gennemgik ansatte og delegerede desuden flere forskellige brugerkurser, tekniske kurser og informationskurser om sagsbehandling m.m. hos de nationale ansvarlige myndigheder.
English: • Yann LE CAM (patients organisation representative) (vice-chairman)
Danish: • Yann LE CAM
English: Chair: To be appointed EMEA contact: Agnès SAINT-RAYMOND
Danish: Formand: endnu ikke udpeget EMEA-kontakt: Agnès SAINT-RAYMOND
English: Ended positively in 2004*
Danish: Afsluttet med positivt resultat i
English: Applications for orphan medicinal product designation Withdrawals
Danish: af lægemidler til sjældne sygdomme Tilbagekaldelser
English: 185 days
Danish: 202 days 185 days
English: CHMP Efficacy Working Party
Danish: CHMP's arbejdsgruppe vedrørende virkninger
English: CVMP opinions in 2004 on medicinal products for veterinary use 11.
Danish: IT-projekter og operationelle aktiviteter CHMP-udtalelser i 2004 om humanmedicinske lægemidler 10. CVMP-udtalelser i 2004 om veterinærlægemidler 11.
English: Alimentary tract and metabolism
Danish: Fordøjelsessystem og stofskifte
English: Scientific advice and orphan drugs
Danish: Videnskabelig rådgivning og lægemidler til sjældne sygd.
English: Head of Sector
Danish: Sektionsleder
English: comb.
Danish: Hum.
English: 2.1 Orphan medicinal products
Danish: 2.1 Lægemidler til sjældne sygdomme
English: 303 days
Danish: 183 days 303 days
English: Meloxicam !
Danish: o leukæmi.
English: 363 days
Danish: 168 days 363 days
English: Felin Interferon !
Danish: Virbagen Omega Felin Interferon Part A
English: Acting Head of Sector for safety and efficacy of medicines
Danish: Fungerende sektionsleder - lægemidlers sikkerhed og virkninger
English: Finalisation expected in 2nd quarter
Danish: Forventes afsluttet i 2. kvartal 2005
English: Arbitration and Community referrals overview 2004
Danish: Oversigt over voldgiftssager og henvisningssager i 2004 14.
English: 148 days
Danish: 183 days 148 days
English: 155 days
Danish: 210 days 155 days
English: Antoine SAWAYA (France) Alternate: Jacqueline VIGUET POUPELLOZ
Danish: Antoine SAWAYA (Frankrig) suppleant: Jacqueline VIGUET POUPELLOZ Vittorio SILANO (Italien) suppleant: Marisa DELBÓ Panayiotis TRIANTAFYLLIS (Cypern) suppleant: Maria STAVROU Arnold J VLIETINCK (Belgien) suppleant: Heidi NEEF
English: 120 days
Danish: 203 days 120 days
English: General anti-infectives for systemic use Anti-neoplastic and immunomodulating agents Nervous system Various
Danish: Generelle antibiotika til systemisk brug Antineoplast.
English: Deputy Head of Sector for safety and efficacy of medicines
Danish: Vicesektionsleder - lægemidlers sikkerhed og virkninger
English: 279 days
Danish: 206 days 279 days
English: 208 days !
Danish: 208 days 180 days
English: Consultation ended in December
Danish: Høring afsluttet i december 2004
English: Initial evaluation opinions and withdrawals
Danish: Ansøgninger om indledende vurdering
English: Scientific Advice Working Party (formerly Scientific Advice Working Group) Chair: Markku TOIVONEN EMEA contact: Agnès SAINT-RAYMOND
Danish: Formand: Markku TOIVONEN EMEA-kontakt: Agnès SAINT-RAYMOND
English: Azilect !
Danish: Ansøgn.
English: EU-US FDA confidentiality arrangements
Danish: Aftale mellem EU og US Food and Drug Administration (FDA)
English: EU and non-EU adverse drug reaction reports
Danish: Indberetninger af bivirkninger (EU og ikke-EU) 2002-2004
English: 153 days
Danish: 172 days 153 days
English: MRL summary opinions are published following their adoption by the CVMP.
Danish: Når CVMP har vedtaget en udtalelse om en maksimal grænseværdi, offentliggøres der et resumé af udtalelsen.
English: 284 days
Danish: 181 days 284 days
English: Part B Extension
Danish: Aloxi palonosetron Part B
English: insulin glulisine !
Danish: Apidra insulin glulisine Part A
English: Haematology
Danish: Hæmatologi
English: Therapeutic area EMEA/CVMP European Commission
Danish: EMEA/CVMP Godkendelse Udtalelse Nettotid Urstop
English: Chair: Hans HOOGLAND EMEA contact: Kornelia GREIN
Danish: (Midlertidig) arbejdsgruppe vedrørende miljørisikovurdering Formand: Hans HOOGLAND EMEA-kontakt: Kornelia GREIN
English: strontium ranelate !
Danish: Protelos strontium ranelate Part B
English: Type of referral
Danish: Type II-ændr.
English: Neurology/CNS
Danish: Neurologi
English: EMEA annual report for 2004 EMEA/61492/2005/EN/Final reporting form aims to ensure consistency of collected information and to foster a common understanding of adverse reaction reporting by practising veterinarians throughout the EU.
Danish: skal sikre større ensartethed i de informationer, der indsamles, og en mere ensartet tilgang til de praktiserende dyrlægers indberetning af bivirkninger overalt i EU.
English: Opinion !
Danish: rådgivn.
English: The expiry date refers to the last day of that month.
Danish: Udløbsdatoen er den sidste dag i nævnte måned.
English: Adults and the elderly
Danish: Voksne og ældre
English: Your doctor will discuss these with you and will explain the potential risks and benefits of your treatment.
Danish: Din læge vil tale med dig om disse og vil forklare de mulige risici og fordele ved din behandling.